Presentation is loading. Please wait.

Presentation is loading. Please wait.

A randomized study of tenofovir containing HAART compared to lamivudine containing HAART in antiretroviral naïve HIV/HBV coinfected patients in Thailand:

Published by个 郑 Modified over 7 years ago

Similar presentations

Presentation on theme: "A randomized study of tenofovir containing HAART compared to lamivudine containing HAART in antiretroviral naïve HIV/HBV coinfected patients in Thailand:"— Presentation transcript:

1 A randomized study of tenofovir containing HAART compared to lamivudine containing HAART in antiretroviral naïve HIV/HBV coinfected patients in Thailand: 48 week findings Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknitmitr R, Petcharat P, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, Ruxrungtham K, Dore GJ

2 Background Prevalence of HBV in HIV populations ~ 5 -10%
HIV/HBV coinfected individuals have high rates of progression to significant liver disease Lamivudine monotherapy for HBV results in high rates of drug resistance Evidence for optimal therapy of HBV in HIV coinfected individuals is based predominantly on observational data

3 Study design N=36 Primary objective AZT / LAM / EFV AZT / TDF / EFV
To compare the safety and efficacy of tenofovir (TDF) to lamivudine (LAM) and to combination TDF/LAM in treating HBV in ARV- naive patients with HIV/HBV co-infection over 48 weeks AZT / LAM / EFV Gp 1 VK N=36 AZT / TDF / EFV Gp 2 VK LAM / TDF / EFV Gp 3 VK Week 12 Week 48

4 Study endpoints Primary endpoint
HBV DNA time-weighted change over 48 weeks (DAVG) Secondary endpoints HBV DNA suppression HBeAg/HBsAg seroconversion HBV resistance Hepatic flare events ALT normalisation Change in HIV-RNA and CD4+ /CD8+ counts Histological improvement/reduction in ccc-HBV-DNA

5 Study set-up Australia-Thai collaboration HBV virology
Subject recruitment through HIV-NAT, Bangkok, Thailand Study management NCHECR, Australia HBV virology performed at VIDRL, Australia HBV virology Bayer Versant bDNA assay (2,000 – 108 copies/ml) Roche Taqman assay (LLD 200 c/ml)

6 Study eligibility Inclusion criteria Exclusion criteria
HIV positive and ARV naive HBsAg positive for > 6 months HBV DNA > 105 copies/ml No prior exposure to anti-HBV agents (excl IFN) Exclusion criteria HCV-RNA positive or Anti-HAV IgM positive Acute hepatitis (serum ALT > 1000 U/L) Active opportunistic infection Pregnancy or lactation Concurrent malignancy Decompensated or Child’s C cirrhosis AFP > 3X ULN

7 Baseline characteristics

8 Baseline characteristics : HBV
* Clinical or histological

9 Median HBV reduction 48 weeks
DAVG analysis 4.07 log 4.51 log 4.73 log p=0.700 This graph demonstrates the median HBV reduction over the 48 weeks in the 3 arms and visually you acns ee there is little difference between the groups. This is confirmed by the DAVG analysis which wwasth primary endpoint, demonstarting no significant difference in the values between groups although it was highest in the combination group.

10 HBV DNA suppression at 48 w
On treatment

11 HBV resistance M204V/L180M HBV DNA reduction (log10 c/ml) No PCR M204I
BL wk 4 wk 8 wk 12 wk 24 wk 36 wk 48 -1 M204V/L180M -2 No PCR HBV DNA reduction (log10 c/ml) -3 M204I -4 WT -5 -6

12 CD4 change P=0.048 P=0.072

13 HIV RNA suppression ITT

14 Hepatic flare Incidence 25% sAg loss Anti-HBE Anti-HBE sAg loss
Reasons for hepatic flare in patients with HIV HBV who initiate HAART may be multifactoiral, and include drug toxicity, flare in HBV disease and immune reconstitution disease. In our patients hepatic falre was followed by seroconversion to anti-HBE in 2 and to anti-HBe followed by anti-HBs in two.

15 Serological response Group 1 LAM Group 2 TDF Group 3 LAM/TDF Total
HBeAg loss* 3 (33%) 1 (17%) 3 (43%) 7 (32%) Anti-HBe Seroconversion* 1 (11%) 6 (27%) HBsAg loss 1 (8%) 1 (9%) 3 (8%) * Of 22 HBeAg positive at BL p=1.00

16 Conclusions Combination TDF/LAM not demonstrated as superior to monotherapy in this study Proportion of patients with HBV DNA > 3 log c/ml at week 48 significantly greater in LAM monotherapy arm 2 cases of LAM resistance both in GP 1 Good HIV control was achieved and maintained in the majority Both seroconversion and hepatic flare common after HBV-active HAART in this population

17 Acknowledgements HIV-NAT Thai Red Cross AIDS Research Centre, Bangkok, Thailand Anchalee Avihingsanon Kiat Ruxrungtham R Rerknitmitr P Petcharat Peeraporn Kaewon National Centre in HIV Epidemiology and Clinical Research Greg Dore David Cooper Pip Marks Janaki Amin Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia Stephen Locarnini Scott Bowden Anna Ayres Peter Revill The Alfred Hospital, Melbourne Sharon Lewin Joe Sasadeusz Jenny Hoy

Download ppt "A randomized study of tenofovir containing HAART compared to lamivudine containing HAART in antiretroviral naïve HIV/HBV coinfected patients in Thailand:"

Similar presentations

Hepatitis B & Hepatitis C in HIV

Hepatitis B & Hepatitis C in HIV
HBV and HIV HIV and HBV VG Naidoo Gastroenterology.

HBV and HIV HIV and HBV VG Naidoo Gastroenterology.
Lessons from a decade of collaboration in Thailand Sharon R Lewin Professor and Head, Department of Infectious Diseases Alfred Hospital and Monash University.

Lessons from a decade of collaboration in Thailand Sharon R Lewin Professor and Head, Department of Infectious Diseases Alfred Hospital and Monash University.
BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A. www.bordernet.eu www.aidshilfe-potsdam.de.

BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A.
Hepatitis web study H EPATITIS W EB S TUDY Therapeutic Agents Used to Treat Hepatitis B Presentation Prepared by: Nina Kim, MD and David Spach, MD Last.

Hepatitis web study H EPATITIS W EB S TUDY Therapeutic Agents Used to Treat Hepatitis B Presentation Prepared by: Nina Kim, MD and David Spach, MD Last.
PEPFAR Hepatitis B co-infection and Response to Antiretroviral Therapy among HIV-infected Patients in Tanzania Oral abstract # MOAB0101 C. Hawkins, B.

PEPFAR Hepatitis B co-infection and Response to Antiretroviral Therapy among HIV-infected Patients in Tanzania Oral abstract # MOAB0101 C. Hawkins, B.
Slide #1 CL Thio, MD. Presented at RWCA Clinical Update, August 2006. Optimizing Hepatitis B Virus Treatment in HIV-Infected Individuals Chloe L. Thio,

Slide #1 CL Thio, MD. Presented at RWCA Clinical Update, August Optimizing Hepatitis B Virus Treatment in HIV-Infected Individuals Chloe L. Thio,
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.

Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Yves BENHAMOU. Management of Patients with HIV/HBV Co-infection Yves Benhamou Hepatology Department Groupe Hospitalier Pitié Salpétrière Paris, France.

Yves BENHAMOU. Management of Patients with HIV/HBV Co-infection Yves Benhamou Hepatology Department Groupe Hospitalier Pitié Salpétrière Paris, France.
HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.

HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
Pathogenesis of HIV-hepatitis B co-infection Sharon R Lewin, FRACP, PhD Infectious Diseases Unit, Alfred Hospital Department of Medicine, Monash University.

Pathogenesis of HIV-hepatitis B co-infection Sharon R Lewin, FRACP, PhD Infectious Diseases Unit, Alfred Hospital Department of Medicine, Monash University.
Switch to LPV/r monotherapy  Pilot LPV/r  M03-613  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.

Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Switch to LPV/r monotherapy  Pilot LPV/r  M03-613  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.

Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Discussion HBV Flare AWACC 2009. Pathogenesis of HBV CLDx Hepatic damage  predominantly immune mediated - cytotoxic T cells HBV specific peptides presented.

Discussion HBV Flare AWACC Pathogenesis of HBV CLDx Hepatic damage  predominantly immune mediated - cytotoxic T cells HBV specific peptides presented.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.

Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.

POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.
Entecavir Superior to Lamivudine for Treatment of Nucleoside-Naive, HBeAg- Negative Patients Slideset on: Lai CL, Shouval D, Lok AS, et al. Entecavir versus.

Entecavir Superior to Lamivudine for Treatment of Nucleoside-Naive, HBeAg- Negative Patients Slideset on: Lai CL, Shouval D, Lok AS, et al. Entecavir versus.

Similar presentations

Ads by Google